PROJECTED COST-EFFECTIVENESS OF EXENATIDE ONCE WEEKLY VERSUS EXENATIDE BID FOR THE TREATMENT OF TYPE 2 DIABETES IN THE UK

被引：0
|
作者：
Wilson, B. P. [1 ]
Beaudet, A. [2 ]
Caputo, J. [3 ]
Timlin, L. [4 ]
机构：
[1] Eli Lilly & Co, London, Hants, England
[2] IMS Consulting Grp, Basel, Switzerland
[3] IMS Consulting Grp, London, England
[4] Eli Lilly & Co, London, Surrey, England
来源：
VALUE IN HEALTH | 2011年 / 14卷 / 07期
关键词：
D O I：
10.1016/j.jval.2011.08.1330
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A476 / A476
页数：1
相关论文
共 50 条
  • [41] Real-world comparative effectiveness of exenatide once weekly and liraglutide in patients with type 2 diabetes mellitus
    Saunders, W.
    Nguyen, H. Hiep
    Kalsekar, I.
    [J]. DIABETOLOGIA, 2014, 57 : S335 - S336
  • [42] Evaluation of the long-term cost-effectiveness of once-weekly semaglutide versus dulaglutide for treatment of type 2 diabetes mellitus in the UK
    Viljoen, Adie
    Hoxer, Christina S.
    Johansen, Pierre
    Malkin, Samuel
    Hunt, Barnaby
    Bain, Stephen C.
    [J]. DIABETES OBESITY & METABOLISM, 2019, 21 (03): : 611 - 621
  • [43] Real-World Comparative Effectiveness of Exenatide Once Weekly and Liraglutide in Patients with Type 2 Diabetes Mellitus
    Saunders, William
    Nguyen, Hiep
    Kalsekar, Iftekhar
    [J]. DIABETES, 2014, 63 : A310 - A310
  • [44] Tolerability, Pharmacokinetics and Pharmacodynamics of Exenatide Once Weekly in Japanese Patients with Type 2 Diabetes
    Iwamoto, Kazuya
    Nasu, Risa
    Yamamura, Ayuko
    Kothare, Prajakti A.
    Wolka, Anne M.
    Linnebjerg, Helle
    [J]. DIABETES, 2009, 58 : A163 - A163
  • [45] Pathophysiological and Pharmacological Rationale for the Use of Exenatide Once Weekly in Patients with Type 2 Diabetes
    Samuel S. Grossman
    [J]. Advances in Therapy, 2014, 31 : 247 - 263
  • [46] Cost-effectiveness of exenatide versus insulin glargine for the treatinent of type 2 diabetes in a UK setting: a long-term health economic study
    Ray, J. A.
    Secnik, K.
    Yurgin, N.
    Valentine, W. J.
    Roze, S.
    McKendrick, J.
    Foos, V.
    Palmer, A. J.
    [J]. DIABETOLOGIA, 2006, 49 : 477 - 477
  • [47] Exenatide once weekly did not affect the QTc interval in patients with type 2 diabetes
    Sager, P.
    Darpo, B.
    Han, J.
    Cirincione, B.
    Linnebjerg, H.
    Mitchell, M.
    Porter, L.
    [J]. DIABETOLOGIA, 2011, 54 : S325 - S326
  • [48] Pathophysiological and Pharmacological Rationale for the Use of Exenatide Once Weekly in Patients with Type 2 Diabetes
    Grossman, Samuel S.
    [J]. ADVANCES IN THERAPY, 2014, 31 (03) : 247 - 263
  • [49] THE IMPACT OF LONG-TERM CLINICAL EVIDENCE ON COST-EFFECTIVENESS OF EXENATIDE ONCE WEEKLY (BYDUREON®) VERSUS INSULIN GLARGINE FOR PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) FROM A UK NHS PERSPECTIVE
    Charokopou, M.
    Vioix, H.
    Verheggen, B. G.
    Bratt, T.
    Franks, D.
    [J]. VALUE IN HEALTH, 2014, 17 (07) : A343 - A343
  • [50] Cost Effectiveness of Once-Weekly Semaglutide Versus Once-Weekly Dulaglutide in the Treatment of Type 2 Diabetes in Canada
    Pierre Johansen
    Jonas Håkan-Bloch
    Aiden R. Liu
    Peter G. Bech
    Sofie Persson
    Lawrence A. Leiter
    [J]. PharmacoEconomics - Open, 2019, 3 : 537 - 550
12345